Interim report
Page 1
August 10, 2026 BSE Limited Corporate Relationship Department Phiroze Jeejeebhoy Towers 25th floor, Dalal Street Mumbai - 400 001 Scrip Code: 543245 National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor Plot no. C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Symbol: GLAND (ISIN: INE068V01023) Dear Sir/Madam, Sub: Outcome of the Board Meeting In continuation to our intimation dated July 24, 2026, regarding the Board Meeting Notice, we would like to inform you that the Board of Directors (the “ Board”) of Gland Pharma Limited (the “ Company”) at its Meeting held today, i.e. Monday, August 10, 2026, has inter-alia considered and approved the Unaudited Financial Results (standalone and consolidated) along with the Limited Review Report(s) for the quarter ended June 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( Listing Regulations’) which has been duly reviewed and recommended by the Audit Committee. In this regard, please find enclosed copies of the: 1. Unaudited Financial Results (standalone and consolidated) along with Limited Review Report(s) of the Company for the quarte r ended June 30, 2026 prepared in compliance with Indian Accounting Standards (Ind AS) 2. Press Release and Investor Presentation on the financial results of the Company for the above period. The Board Meeting commenced at 15.00 Hrs. IST and ended at 16.05 Hrs. IST. This is for your information and records. Yours truly, For Gland Pharma Limited Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer Encl: As above GLAND PHARMA LIMITEDAugust 10, 2026BSE LimitedCorporate Relationship DepartmentPhiroze Jeejeebhoy Towers25thfloor, Dalal StreetMumbai - 400 001Scrip Code: 543245 National Stock Exchange of India LimitedListing DepartmentExchange Plaza, 5th floorPlot no. C-l, Block G, Bandra Kurla Complex Bandra(East), Mumbai - 400 051Symbol: GLAND (ISIN: INE068V01023)Dear Sir/Madam,Sub: Outcome of the Board MeetingIn continuation to our intimation dated July 24, 2026, regarding the Board Meeting Notice, we would like toinform you that the Board of Directors (the “Board”) of Gland Pharma Limited (the “Company”) at itsMeeting held today, i.e. Monday, August 10, 2026, has inter-alia considered and approved the UnauditedFinancial Results (standalone and consolidated) along with the Limited Review Report(s) for the quarter endedJune 30, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015 (Listing Regulations’) which has been duly reviewed and recommended by the AuditCommittee.In this regard, please find enclosed copies of the:1. Unaudited Financial Results (standalone and consolidated) along with Limited Review Report(s)of the Company for the quarter ended June 30, 2026 prepared in compliance with IndianAccounting Standards (Ind AS)2. Press Release and Investor Presentation on the financial results of the Company for the aboveperiod.The Board Meeting commenced at 15.00 Hrs. 1ST and ended at 16.05 Hrs. 1ST.This is for your information and records.Yours truly,For Gland Pharma Limited Sampath Kumar PallerlamudiCompany Secretary & Compliance OfficerEncl: As above Regd. Office: Corporate Office:Survey No. 143-148, 150 & 151, Near Gandimaisamma ‘X’ Roads Plot No. 11 & 84, TSIIC Phase: IVD.P. Pally, Dundigal, Dundigal-Gandimaisamma Mandal Pashamylaram (V), Patancheru (M), Sangareddy DistrictMedchal-Malkajgiri District, Hyderabad 500043,Telangana, India Hyderabad 502307, Telangana, IndiaTel: +91-40-30510999 Fax: +91-40-30510800 Tel: +91-8455-699999CIN: L24239TG1978PLC002276 | email: gland@glandpharma.com; investors@glandpharma.com | www.glandpharma.com
Page 2
Chartered AccountantsMeenakshi Pride Rock-Tower 111 [Block-M], 8th & 9th Floors,Survey No, 23, Gachibowli,Serilingampally MunicipalityRanga Reddy District,Hyderabad-500032Telangana, India DeloitteHaskins & Sells INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTSTO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Gland Pharma Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (”Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations Our responsibility is to express a conclusion on the Statement based on our review.3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Holding Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, as amended, to the extent applicable.4. The Statement includes the results of the following entities: Sri.No.Name of the entityRelationship1Gland Pharma LimitedHolding Company 2Gland Pharma International Pte. Ltd., SingaporeWholly-owned subsidiary Subsidiaries of Gland Pharma International Pte. Ltd.: 3Gland Pharma USA Inc., USA “1 4Phixen SAS, France <- —Wholly-owned subsidiaries Subsidiaries of Phixen SAS: 5Cenexi SAS, France6Cenexi HSC SAS, France7Cenexi Laboratories Thissen SA, BelgiumWholly-owned subsidiaries 8Phineximmo SA, Belgium9Gland Pharma Europe SAS, France Chartered AccountantsMeenakshi Pride Rock-Tower HI [Block -M], 8th & 9th Floors,Survey No. 23, Gachibowh,Serilmgampally MunicipalityRanga Reddy District,Hyderabad-500032Telangana, India DeloitteHaskins & Sells INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTSTO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Gland Pharma Limited ("the Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations Our responsibility is to express a conclusion on the Statement based on our review.3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Holding Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less m scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, as amended, to the extent applicable.4. The Statement includes the results of the following entities: Sri.No.Name of the entityRelationship1Gland Pharma LimitedHolding Company 2Gland Pharma International Pte. Ltd., SingaporeWholly-owned subsidiary Subsidiaries of Gland Pharma International Pte. Ltd.: 3Gland Pharma USA Inc., USA “1 4Phixen SAS, France r *—Wholly-owned subsidiaries Subsidiaries of Phixen SAS: __ 5Cenexi SAS, France6Cenex! HSC SAS, France7Cenexi Laboratories Thissen SA, BelgiumWholly-owned subsidiaries 8Phineximmo SA, Belgium9Gland Pharma Europe SAS, France Chartered AccountantsMeenakshi Pride Rock-Tower HI [Block -M], 8th & 9th Floors,Survey No. 23, Gachibowh,Serilmgampally MunicipalityRanga Reddy District,Hyderabad-500032Telangana, India DeloitteHaskins & Sells INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTSTO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Gland Pharma Limited ("the Holding Company”) and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2026 ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations Our responsibility is to express a conclusion on the Statement based on our review.3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Holding Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less m scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, as amended, to the extent applicable.4. The Statement includes the results of the following entities: Sri.No.Name of the entityRelationship1Gland Pharma LimitedHolding Company 2Gland Pharma International Pte. Ltd., SingaporeWholly-owned subsidiary Subsidiaries of Gland Pharma International Pte. Ltd.: 3Gland Pharma USA Inc., USA “1 4Phixen SAS, France r *—Wholly-owned subsidiaries Subsidiaries of Phixen SAS: __ 5Cenexi SAS, France6Cenexi HSC SAS, France7Cenexi Laboratories Thissen SA, BelgiumWholly-owned subsidiaries 8Phineximmo SA, Belgium9Gland Pharma Europe SAS, France
Page 3
DeloitteHaskins & Sells5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has corne to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.6. We did not review the interim financial information of two subsidiaries included in the consolidated unaudited financial results, whose financial information reflects total revenues of ? 1,654.54 million, total profit after tax of ? 82.44 million and total comprehensive income of ? 82.44 million for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter. 7. The unaudited consolidated financial results includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of ? Nil, total loss after tax of ? 1.78 million and total comprehensive loss of ? 1.78 million for the quarter ended June 30, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on this interim financial information certified by the Management. For Deloitte Haskins & SellsChartered Accountants(Firm's Registration No. 008082S) Monisha ParikhPartnerMembership No. 047840UDIN: 26047840AVXSXI6758Place: BengaluruDate: August 10, 2026 DeloitteHaskins & Sells5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has corne to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.6. We did not review the interim financial information of two subsidiaries included in the consolidated unaudited financial results, whose financial information reflects total revenues of ? 1,654.54 million, total profit after tax of ? 82.44 million and total comprehensive income of ? 82.44 million for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter. 7. The unaudited consolidated financial results includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of ? Nil, total loss after tax of ? 1.78 million and total comprehensive loss of ? 1.78 million for the quarter ended June 30, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on this interim financial information certified by the Management. For Deloitte Haskins & SellsChartered Accountants(Firm's Registration No. 008082S) Monisha ParikhPartnerMembership No. 047840UDIN: 26047840AVXSXI6758Place: BengaluruDate: August 10, 2026 DeloitteHaskins & Sells5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to m paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.6. We did not review the interim financial information of two subsidiaries included in the consolidated unaudited financial results, whose financial information reflects total revenues of ? 1,654.54 million, total profit after tax of ? 82.44 million and total comprehensive income of ? 82.44 million for the quarter ended June 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of this matter. 7. The unaudited consolidated financial results includes the interim financial information of two subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total revenue of ? Nil, total loss after tax of ? 1.78 million and total comprehensive loss of ? 1.78 million for the quarter ended June 30, 2026, as considered in the Statement. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group. Our conclusion on the Statement is not modified in respect of our reliance on this interim financial information certified by the Management. For Deloitte Haskins & SellsChartered Accountants(Firm's Registration No. 008082S) Monisha ParikhPartnerMembership No. 047840UDIN: 26047840AVXSXI6758Place: BengaluruDate: August 10, 2026
Page 4
GLAND PHARMA LIMITEDCorporate Identity Number: L24239TG1978PLC002276Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma ‘X’ Roads, D.P. Pally, Dundigal Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.comStatement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026(? in million) ParticularsQuarter endedYear ended 30-Jun-2631-Mar-2630-Jun-2531-Mar-26UnauditedUnauditedUnauditedAudited 1. IncomeRevenue from operationsOther incomeTotal income2. ExpensesCost of materials consumedPurchase of stock-in-tradeChanges in inventories of finished goods, stock-in-trade and work-in-progressPower and fuelEmployee benefits expenseDepreciation and amortisation expenseFinance costsOther expensesTotal expenses3. Profit before exceptional item and tax (1-2) 4. Exceptional item (refer note 3) 5. Profit before tax (3-4)6. Tax expenseCurrent taxDeferred taxTaxes of earlier yearsTotal tax expense7. Profit for the quarter/year (5-6) Attributable to:- Owners of the Company- Non-controlling interests8. Other comprehensive incomeItems that will not be reclassified subsequently to profit or loss: Remeasurement of defined benefit plans Deferred tax impact on remeasurement of defined benefit plans Items that will be reclassified subsequently to profit or loss: Exchange differences on translation of foreign operationsTotal other comprehensive (income)/loss, net of tax 9. Total comprehensive income (7-8) Attributable to:- Owners of the Company- Non-controlling interests10. Paid up equity share capital (Face value of ?1/- each) 11. Other equity12. Earnings per equity share (Face value of ?1/- each): (Not annualisedfor the quarter)Basic (?)Diluted (?) 18,002.71612.2817,427.901,114.6615,056.22575.2764,306.503,163.2818,614.9918,542.5615,631.4967,469.785,882.0119.45341.84558.774,439.981,112.5843.611,866.99 5,940.7022.78(50.17)530.184,115.741,086.60100.301,738.47 5,573.628.81(371.08)456.564,080.381,010.52114.961,630.31 22,397.4966.04(34.23)2,028.5216,288.394,236.67332.797,264.8514,265.2313,484.6012,504.0852,580.524,349.765,057.963,127.4114,889.264,349.761,267.62(74.75)(12.70) 5,057.961,439.60(48.50)0.11 3,127.411,010.51(47.36)9.44 243.4614,645.804,578.14(215.95)10.45 1,180.171,391.21972.594,372.643,169.593,666.752,154.8210,273.163,169.59 (25.13)6.35285.95 3,666.75 (66.25)31.47(974.36) 2,154.82 13.34(2.46)(1,875.77) 10,273.16 (135.62)34.45(4,208.70)267.17(1,009.14)(1,864.89)(4,309.87)2,902.424,675.894,019.7114,583.032,902.42164.96 19.2319.22 4,675.89164.76 22.2622.23 4,019.71164.76 13.0813.08 14,583.03164.76103,414.7462.3562.28 GLAND PHARMA LIMITEDCorporate Identity Number: L24239TG1978PLC002276Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma ‘X’ Roads, D.P. Pally, Dundigal Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.comStatement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026(? in million) ParticularsQuarter endedYear ended 30-Jun-2631-Mar-2630-Jun-2531-Mar-26UnauditedUnauditedUnauditedAudited 1. IncomeRevenue from operationsOther incomeTotal income2. ExpensesCost of materials consumedPurchase of stock-in-tradeChanges in inventories of finished goods, stock-in-trade and work-in-progressPower and fuelEmployee benefits expenseDepreciation and amortisation expenseFinance costsOther expensesTotal expenses3. Profit before exceptional item and tax (1-2) 4. Exceptional item (refer note 3) 5. Profit before tax (3-4)6. Tax expenseCurrent taxDeferred taxTaxes of earlier yearsTotal tax expense7. Profit for the quarter/year (5-6) Attributable to:- Owners of the Company- Non-controlling interests8. Other comprehensive incomeItems that will not be reclassified subsequently to profit or loss: Remeasurement of defined benefit plans Deferred tax impact on remeasurement of defined benefit plans Items that will be reclassified subsequently to profit or loss: Exchange differences on translation of foreign operationsTotal other comprehensive (income)/loss, net of tax 9. Total comprehensive income (7-8) Attributable to:- Owners of the Company- Non-controlling interests10. Paid up equity share capital (Face value of ?1/- each) 11. Other equity12. Earnings per equity share (Face value of ?1/- each): (Not annualisedfor the quarter)Basic (?)Diluted (?) 18,002.71612.2817,427.901,114.6615,056.22575.2764,306.503,163.2818,614.9918,542.5615,631.4967,469.785,882.0119.45341.84558.774,439.981,112.5843.611,866.99 5,940.7022.78(50.17)530.184,115.741,086.60100.301,738.47 5,573.628.81(371.08)456.564,080.381,010.52114.961,630.31 22,397.4966.04(34.23)2,028.5216,288.394,236.67332.797,264.8514,265.2313,484.6012,504.0852,580.524,349.765,057.963,127.4114,889.264,349.761,267.62(74.75)(12.70) 5,057.961,439.60(48.50)0.11 3,127.411,010.51(47.36)9.44 243.4614,645.804,578.14(215.95)10.45 1,180.171,391.21972.594,372.643,169.593,666.752,154.8210,273.163,169.59 (25.13)6.35285.95 3,666.75 (66.25)31.47(974.36) 2,154.82 13.34(2.46)(1,875.77) 10,273.16 (135.62)34.45(4,208.70)267.17(1,009.14)(1,864.89)(4,309.87)2,902.424,675.894,019.7114,583.032,902.42164.96 19.2319.22 4,675.89164.76 22.2622.23 4,019.71164.76 13.0813.08 14,583.03164.76103,414.7462.3562.28 GLAND PHARMA LIMITEDCorporate Identity Number: L24239TG1978PLC002276Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma ‘X’ Roads, D.P. Pally, Dundigal Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.comStatement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026(? in million) ParticularsQuarter endedYear ended 30-Jun-2631-Mar-2630-Jun-2531-Mar-26UnauditedUnauditedUnauditedAudited 1. IncomeRevenue from operationsOther incomeTotal income2. ExpensesCost of materials consumedPurchase of stock-in-tradeChanges in inventories of finished goods, stock-in-trade and work-in-progressPower and fuelEmployee benefits expenseDepreciation and amortisation expenseFinance costsOther expensesTotal expenses3. Profit before exceptional item and tax (1-2) 4. Exceptional item (refer note 3) 5. Profit before tax (3-4)6. Tax expenseCurrent taxDeferred taxTaxes of earlier yearsTotal tax expense7. Profit for the quarter/year (5-6) Attributable to:- Owners of the Company- Non-controlling interests8. Other comprehensive incomeItems that will not be reclassified subsequently to profit or loss: Remeasurement of defined benefit plans Deferred tax impact on remeasurement of defined benefit plans Items that will be reclassified subsequently to profit or loss: Exchange differences on translation of foreign operationsTotal other comprehensive (income)/loss, net of tax 9. Total comprehensive income (7-8) Attributable to:- Owners of the Company- Non-controlling interests10. Paid up equity share capital (Face value of ?1/- each) 11. Other equity12. Earnings per equity share (Face value of ?1/- each): (Not annualisedfor the quarter)Basic (?)Diluted (?) 18,002.71612.2817,427.901,114.6615,056.22575.2764,306.503,163.2818,614.9918,542.5615,631.4967,469.785,882.0119.45341.84558.774,439.981,112.5843.611,866.99 5,940.7022.78(50.17)530.184,115.741,086.60100.301,738.47 5,573.628.81(371.08)456.564,080.381,010.52114.961,630.31 22,397.4966.04(34.23)2,028.5216,288.394,236.67332.797,264.8514,265.2313,484.6012,504.0852,580.524,349.765,057.963,127.4114,889.264,349.761,267.62(74.75)(12.70) 5,057.961,439.60(48.50)0.11 3,127.411,010.51(47.36)9.44 243.4614,645.804,578.14(215.95)10.45 1,180.171,391.21972.594,372.643,169.593,666.752,154.8210,273.163,169.59 (25.13)6.35285.95 3,666.75 (66.25)31.47(974.36) 2,154.82 13.34(2.46)(1,875.77) 10,273.16 (135.62)34.45(4,208.70)267.17(1,009.14)(1,864.89)(4,309.87)2,902.424,675.894,019.7114,583.032,902.42164.96 19.2319.22 4,675.89164.76 22.2622.23 4,019.71164.76 13.0813.08 14,583.03164.76103,414.7462.3562.28 GLAND PHARMA LIMITEDCorporate Identity Number: L24239TG1978PLC002276Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma ‘X’ Roads, D.P. Pally, Dundigal Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandpharma.com; E-mail: investors@glandpharma.comStatement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026 GLAND(? in million) ParticularsQuarter endedYear ended 30-Jun-2631-Mar-2630-Jun-2531-Mar-26UnauditedUnauditedUnauditedAudited 1. IncomeRevenue from operationsOther incomeTotal income2. ExpensesCost of materials consumedPurchase of stock-in-tradeChanges in inventories of finished goods, stock-in-trade and work-in-progressPower and fuelEmployee benefits expenseDepreciation and amortisation expenseFinance costsOther expensesTotal expenses3. Profit before exceptional item and tax (1-2) 4. Exceptional item (refer note 3) 5. Profit before tax (3-4)6. Tax expenseCurrent taxDeferred taxTaxes of earlier yearsTotal tax expense7. Profit for the quarter/year (5-6) Attributable to:- Owners of the Company- Non-controlling interests8. Other comprehensive incomeItems that will not be reclassified subsequently to profit or loss: Remeasurement of defined benefit plans Deferred tax impact on remeasurement of defined benefit plans Items that will be reclassified subsequently to profit or loss: Exchange differences on translation of foreign operationsTotal other comprehensive (income)Zloss, net of tax 9. Total comprehensive income (7-8) Attributable to:- Owners of the Company- Non-controlling interests10. Paid up equity share capital (Face value of ?1/- each) 11. Other equity12. Earnings per equity share (Face value of ?1/- each): (Not annualisedfor the quarter)Basic (?)Diluted (?) 18,002.71612.2817,427.901,114.6615,056.22575.2764,306.503,163.2818,614.9918,542.5615,631.4967,469.785,882.0119.45341.84558.774,439.981,112.5843.611,866.99 5,940.7022.78(50.17)530.184,115.741,086.60100.301,738.47 5,573.628.81(371.08)456.564,080.381,010.52114.961,630.31 22,397.4966.04(34.23)2,028.5216,288.394,236.67332.797,264.8514,265.2313,484.6012,504.0852,580.524,349.765,057.963,127.4114,889.264,349.761,267.62(74.75)(12.70) 5,057.961,439.60(48.50)0.11 3,127.411,010.51(47.36)9.44 243.4614,645.804,578.14(215.95)10.45 1,180.171,391.21972.594,372.643,169.593,666.752,154.8210,273.163,169.59 (25.13)6.35285.95 3,666.75 (66.25)31.47(974.36) 2,154.82 13.34(2.46)(1,875.77) 10,273.16 (135.62)34.45(4,208.70)267.17(1,009.14)(1,864.89)(4,309.87)2,902.424,675.894,019.7114,583.032,902.42164.96 19.2319.22 4,675.89164.76 22.2622.23 4,019.71164.76 13.0813.08 14,583.03164.76103,414.7462.3562.28 &,e(\m□★/
Page 5
Notes:1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026 ("Consolidated Financial Results") of Gland Pharma Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Consolidated Financial Results and issued an unmodified report thereon.2. The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in tenus of the Listing 3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.The Company assessed the implications of the New Labour Codes and made an additional provision of ? 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item". 4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.5. The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation. 7. The above Unaudited Consolidated Financial Results of the Group are available on the Company’s website www.glandpharma.com and also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), where the equity shares of the Company are listed. GLANDFor and on behalf of the BoardGland Pharma Limited \<JPtZI CHARTEREDO I ACCOUNTANTS) mSrinivas SaduExecutive ChairmanDIN No. 06900659 HyderabadAugust 10, 2026 Notes:1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026 ("Consolidated Financial Results") of Gland Pharma Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Consolidated Financial Results and issued an unmodified report thereon.2. The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in tenus of the Listing 3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.The Company assessed the implications of the New Labour Codes and made an additional provision of ? 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item". 4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.5. The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation. 7. The above Unaudited Consolidated Financial Results of the Group are available on the Company’s website www.glandpharma.com and also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), where the equity shares of the Company are listed. GLANDFor and on behalf of the BoardGland Pharma Limited \<JPtZI CHARTEREDO I ACCOUNTANTS) mSrinivas SaduExecutive ChairmanDIN No. 06900659 HyderabadAugust 10, 2026 Notes:1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026 ("Consolidated Financial Results") of Gland Pharma Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Consolidated Financial Results and issued an unmodified report thereon.2. The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in tenus of the Listing 3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.The Company assessed the implications of the New Labour Codes and made an additional provision of ? 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item". 4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.5. The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation. 7. The above Unaudited Consolidated Financial Results of the Group are available on the Company’s website www.glandpharma.com and also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), where the equity shares of the Company are listed. GLANDFor and on behalf of the BoardGland Pharma Limited \<JPtZI CHARTEREDO I ACCOUNTANTS) mSrinivas SaduExecutive ChairmanDIN No. 06900659 HyderabadAugust 10, 2026 Notes:1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Consolidated Financial Results for the quarter ended June 30, 2026 ("Consolidated Financial Results") of Gland Pharma Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Consolidated Financial Results and issued an unmodified report thereon.2. The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of the Listing 3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.The Company assessed the implications of the New Labour Codes and made an additional provision of ? 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item". 4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.5. The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation. 7. The above Unaudited Consolidated Financial Results of the Group are available on the Company’s website www.glandpharma.com and also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com), where the equity shares of the Company are listed. 4T,o( ★ \m★/ GLAND!\<? For and on behalf of the BoardGland Pharma Limited Srinivas SaduExecutive ChairmanDIN No. 06900659 HyderabadAugust 10, 2026
Page 6
DeloitteHaskins & SellsChartered AccountantsMeenakshi Pride Rock-Tower HI (Block M], 8th & 9th Floors,Survey No 23, Gachibowli,Scrilingampally MunicipalityRanga Reddy District,Hyderabad 500032Telangana, India INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONEFINANCIAL RESULTSTO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Gland Pharma Limited ("the Company”), for the quarter ended June 30, 2026 ("the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, as amended ("the Listing Regulations”).2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting” ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.For Deloitte Haskins and SellsChartered Accountants(Firm's Registration No.008072S) Monisha ParikhPartnerMembership No. 047840UDIN: 26047840AXSGBU1078Place: BengaluruDate: August 10, 2026 DeloitteHaskins & SellsChartered AccountantsMeenakshi Pride Rock-Tower HI (Block M], 8th & 9th Floors,Survey No 23, Gachibowli,Scrilingampally MunicipalityRanga Reddy District,Hyderabad 500032Telangana, India INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONEFINANCIAL RESULTSTO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Gland Pharma Limited ("the Company”), for the quarter ended June 30, 2026 ("the Statement”), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, as amended ("the Listing Regulations”).2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting” ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.For Deloitte Haskins and SellsChartered Accountants(Firm's Registration No.008072S) Monisha ParikhPartnerMembership No. 047840UDIN: 26047840AXSGBU1078Place: BengaluruDate: August 10, 2026 DeloitteHaskins & SellsChartered AccountantsMeenakshi Pride Rock-Tower 111 IBlock M], 8th & 9th Floors,Survey No 23, Gachibowli,Scribngampally MunicipalityRanga Reddy District,Hyderabad 500032Telangana, India INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONEFINANCIAL RESULTSTO THE BOARD OF DIRECTORS OF GLAND PHARMA LIMITED1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Gland Pharma Limited ("the Company"), for the quarter ended June 30, 2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)Regulations, 2015, as amended ("the Listing Regulations").2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.For Deloitte Haskins and SellsChartered Accountants(Firm's Registration NO.008072S) Monisha ParikhPartnerMembership No. 047840UDIN: 26047840AXSGBU1078Place: BengaluruDate: August 10, 2026
Page 7
GLAND PHARMA LIMITED HM|H| Corporate Identity Number: L24239TG1978PLC002276I HMBHL Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma Roads, D.P. Pally, Dundigal Dundigal - Gandi Maisamma (M), Medchai-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandphanna.com; E-mail: investors@glandpharma.comStatement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026(? in million)Quarter endedYear ended Particulars30-Jun-2631-Mar-2630-Jun-2531-Mar-26UnauditedUnauditedUnauditedAudited 1. IncomeRevenue from operations12,866.4012,615.9210,388.3545,520.92 Other income588.211,063.57547.413,038.97 Total income13,454.6113,679.4910,935.7648,559.89 2. ExpensesCost of materials consumed4,694.464,609.574,398.2417,952.19 Purchase of stock-in-trade19.4522.788.8166.04 Changes in inventories of finished goods, stock-in-trade and358.56215.54(142.18)(66.65) work-in-progressPower and fuel336.32298.24301.211,223.83 Employee benefits expense1,439.091,339.561,284.365,288.18 Depreciation and amortisation expense439.53431.10437.681,762.43 Finance costs6.9161.6574.35180.73 Other expenses1,283.391,053.06949.464,426.57 Total expenses8,577.718,031.507,311.9330,833.32 3. Profit before exceptional item and tax (1-2)4,876.905,647.993,623.8317,726.57 4. Exceptional item (refer note 3)---243.46 5. Profit before tax (3-4)4,876.905,647.993,623.8317,483.11 6. Tax expenseCurrent tax1,264.621,432.14932.714,525.19 Deferred tax(18.93)11.34(1.46)(38.29) Taxes of earlier years(12.70)--0.70 Total tax expense1,232.991,443.48931.254,487.60 7. Profit for the quarter/year (5-6)3,643.914,204.512,692.5812,995.51 8. Other comprehensive incomeItems that will not be reclassified subsequently to profit or loss: Remeasurement of defined benefit plans(21.63)(74.69)9.77(86.51) Deferred tax impact on remeasurement of defined benefit plans5.4418.79(2.46)21.77 Total other comprehensive (income)/loss, net of tax(16.19)(55.90)7.31(64.74) 9. Total comprehensive income (7-8)3,660.104,260.412,685.2713,060.25 10. Paid up equity share capital (Face value of ?1/- each)164.96164.76164.76164.76 11. Other equity107,935.57 12. Earnings per equity share (Face value of ?1/- each): (Not annualised for the quarter)Basic (?)22.1125.5216.3478.88 Diluted (?)22.1025.4916.3478.78 \qp\CHARTERED \ü) O I ACCOUNTANTS/ m w<<> GLAND PHARMA LIMITED HM|H| Corporate Identity Number: L24239TG1978PLC002276I HMBHL Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma Roads, D.P. Pally, Dundigal Dundigal - Gandi Maisamma (M), Medchai-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandphanna.com; E-mail: investors@glandpharma.comStatement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026(? in million)Quarter endedYear ended Particulars30-Jun-2631-Mar-2630-Jun-2531-Mar-26UnauditedUnauditedUnauditedAudited 1. IncomeRevenue from operations12,866.4012,615.9210,388.3545,520.92 Other income588.211,063.57547.413,038.97 Total income13,454.6113,679.4910,935.7648,559.89 2. ExpensesCost of materials consumed4,694.464,609.574,398.2417,952.19 Purchase of stock-in-trade19.4522.788.8166.04 Changes in inventories of finished goods, stock-in-trade and358.56215.54(142.18)(66.65) work-in-progressPower and fuel336.32298.24301.211,223.83 Employee benefits expense1,439.091,339.561,284.365,288.18 Depreciation and amortisation expense439.53431.10437.681,762.43 Finance costs6.9161.6574.35180.73 Other expenses1,283.391,053.06949.464,426.57 Total expenses8,577.718,031.507,311.9330,833.32 3. Profit before exceptional item and tax (1-2)4,876.905,647.993,623.8317,726.57 4. Exceptional item (refer note 3)---243.46 5. Profit before tax (3-4)4,876.905,647.993,623.8317,483.11 6. Tax expenseCurrent tax1,264.621,432.14932.714,525.19 Deferred tax(18.93)11.34(1.46)(38.29) Taxes of earlier years(12.70)--0.70 Total tax expense1,232.991,443.48931.254,487.60 7. Profit for the quarter/year (5-6)3,643.914,204.512,692.5812,995.51 8. Other comprehensive incomeItems that will not be reclassified subsequently to profit or loss: Remeasurement of defined benefit plans(21.63)(74.69)9.77(86.51) Deferred tax impact on remeasurement of defined benefit plans5.4418.79(2.46)21.77 Total other comprehensive (income)/loss, net of tax(16.19)(55.90)7.31(64.74) 9. Total comprehensive income (7-8)3,660.104,260.412,685.2713,060.25 10. Paid up equity share capital (Face value of ?1/- each)164.96164.76164.76164.76 11. Other equity107,935.57 12. Earnings per equity share (Face value of ?1/- each): (Not annualised for the quarter)Basic (?)22.1125.5216.3478.88 Diluted (?)22.1025.4916.3478.78 \qp\CHARTERED \ü) O I ACCOUNTANTS/ m w<<> GLAND PHARMA LIMITED HM|H| Corporate Identity Number: L24239TG1978PLC002276I HMBHL Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma Roads, D.P. Pally, Dundigal Dundigal - Gandi Maisamma (M), Medchai-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandphanna.com; E-mail: investors@glandpharma.comStatement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026(? in million)Quarter endedYear ended Particulars30-Jun-2631-Mar-2630-Jun-2531-Mar-26UnauditedUnauditedUnauditedAudited 1. IncomeRevenue from operations12,866.4012,615.9210,388.3545,520.92 Other income588.211,063.57547.413,038.97 Total income13,454.6113,679.4910,935.7648,559.89 2. ExpensesCost of materials consumed4,694.464,609.574,398.2417,952.19 Purchase of stock-in-trade19.4522.788.8166.04 Changes in inventories of finished goods, stock-in-trade and358.56215.54(142.18)(66.65) work-in-progressPower and fuel336.32298.24301.211,223.83 Employee benefits expense1,439.091,339.561,284.365,288.18 Depreciation and amortisation expense439.53431.10437.681,762.43 Finance costs6.9161.6574.35180.73 Other expenses1,283.391,053.06949.464,426.57 Total expenses8,577.718,031.507,311.9330,833.32 3. Profit before exceptional item and tax (1-2)4,876.905,647.993,623.8317,726.57 4. Exceptional item (refer note 3)---243.46 5. Profit before tax (3-4)4,876.905,647.993,623.8317,483.11 6. Tax expenseCurrent tax1,264.621,432.14932.714,525.19 Deferred tax(18.93)11.34(1.46)(38.29) Taxes of earlier years(12.70)--0.70 Total tax expense1,232.991,443.48931.254,487.60 7. Profit for the quarter/year (5-6)3,643.914,204.512,692.5812,995.51 8. Other comprehensive incomeItems that will not be reclassified subsequently to profit or loss: Remeasurement of defined benefit plans(21.63)(74.69)9.77(86.51) Deferred tax impact on remeasurement of defined benefit plans5.4418.79(2.46)21.77 Total other comprehensive (income)/loss, net of tax(16.19)(55.90)7.31(64.74) 9. Total comprehensive income (7-8)3,660.104,260.412,685.2713,060.25 10. Paid up equity share capital (Face value of ?1/- each)164.96164.76164.76164.76 11. Other equity107,935.57 12. Earnings per equity share (Face value of ?1/- each): (Not annualised for the quarter)Basic (?)22.1125.5216.3478.88 Diluted (?)22.1025.4916.3478.78 \qp\CHARTERED \ü) O I ACCOUNTANTS/ m w<<> GLAND PHARMA LIMITEDCorporate Identity Number: L24239TG1978PLC002276Registered Office: Sy. No. 143 - 148, 150 and 151, Near Gandi Maisamma ‘X’ Roads, D.P. Pally, Dundigal Dundigal - Gandi Maisamma (M), Medchal-Malkajgiri District, Hyderabad 500 043, Telangana, India Tel: +91 84556 99999; Website: www.glandphanna.com; E-mail: investors@glandpharma.comStatement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026(? in million) ParticularsQuarter endedYear ended 30-Jun-2631-Mar-2630-Jun-2531-Mar-26UnauditedUnauditedUnauditedAudited 1. IncomeRevenue from operationsOther incomeTotal income2. ExpensesCost of materials consumedPurchase of stock-in-tradeChanges in inventories of finished goods, stock-in-trade and work-in-progressPower and fuelEmployee benefits expenseDepreciation and amortisation expenseFinance costsOther expensesTotal expenses3. Profit before exceptional item and tax (1-2) 4. Exceptional item (refer note 3) 5. Profit before tax (3-4)6. Tax expenseCurrent taxDeferred taxTaxes of earlier yearsTotal tax expense7. Profit for the quarter/year (5-6) 8. Other comprehensive incomeItems that will not be reclassified subsequently to profit or loss: Remeasurement of defined benefit plans Deferred tax impact on remeasurement of defined benefit plans Total other comprehensive (income)Zloss, net of tax 9. Total comprehensive income (7-8) 10. Paid up equity share capital (Face value of ?1Z- each) 11. Other equity12. Earnings per equity share (Face value of ?1Z- each): (Not annualisedfor the quarter)Basic (?)Diluted (?) 12,866.40588.2112,615.921,063.5710,388.35547.4145,520.923,038.9713,454.6113,679.4910,935.7648,559.894,694.4619.45358.56336.321,439.09439.536.911,283.39 4,609.5722.78215.54298.241,339.56431.1061.651,053.06 4,398.248.81(142.18)301.211,284.36437.6874.35949.46 17,952.1966.04(66.65)1,223.835,288.181,762.43180.734,426.578,577.718,031.507,311.9330,833.324,876.905,647.993,623.8317,726.574,876.901,264.62(18.93)(12.70) 5,647.991,432.1411.343,623.83932.71(1.46) 243.4617,483.114,525.19(38.29)0.70 1,232.991,443.48931.254,487.603,643.914,204.512,692.5812,995.51(21.63)5.44(74.69)18.799.77(2.46)(86.51)21.77 (16.19)(55.90)7.31(64.74) 3,660.104,260.412,685.2713,060.25164.96 22.1122.10 164.76 25.5225.49 164.76 16.3416.34 164.76107,935.5778.8878.78 -f CHARTERED \(J'>O I ACCOUNTANTS! m \5)>\ /'"'I
Page 8
Notes:1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026 ("Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Standalone Financial Results and issued an unmodified report thereon.2. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of the Listing requirements.3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.The Company assessed the implications of the New Labour Codes and made an additional provision of? 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item".4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.5. The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation.7. The above Unaudited Standalone Financial Results of the Company are available on the Company’s website www.glandpharma.comand also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com),where the equity shares of the Company are listed. For and on behalf of the BoardGland Pharma Limited Srinivas SaduExecutive ChairmanDIN No. 06900659 HyderabadAugust 10, 2026 Notes:1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026 ("Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Standalone Financial Results and issued an unmodified report thereon.2. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of the Listing requirements.3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.The Company assessed the implications of the New Labour Codes and made an additional provision of? 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item".4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.5. The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation.7. The above Unaudited Standalone Financial Results of the Company are available on the Company’s website www.glandpharma.comand also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com),where the equity shares of the Company are listed. For and on behalf of the BoardGland Pharma Limited Srinivas SaduExecutive ChairmanDIN No. 06900659 HyderabadAugust 10, 2026 Notes:1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026 ("Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Standalone Financial Results and issued an unmodified report thereon.2. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of the Listing requirements.3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.The Company assessed the implications of the New Labour Codes and made an additional provision of? 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item".4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.5. The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation.7. The above Unaudited Standalone Financial Results of the Company are available on the Company’s website www.glandpharma.comand also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com),where the equity shares of the Company are listed. For and on behalf of the BoardGland Pharma Limited Srinivas SaduExecutive ChairmanDIN No. 06900659 HyderabadAugust 10, 2026 Notes:1. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing requirements"), this Statement of Unaudited Standalone Financial Results for the quarter ended June 30, 2026 ("Standalone Financial Results") of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 10, 2026. The statutory auditors have carried out a limited review on the Unaudited Standalone Financial Results and issued an unmodified report thereon.2. The Unaudited Standalone Financial Results of the Company have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended and read with relevant rules thereunder and in terms of the Listing requirements.3. The Government of India consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz. The Code on Wages, 2019, The Industrial Relations Code, 2020, The Code on Social Security, 2020, and The Occupational Safety, Health and Working Conditions Code, 2020 (collectively referred to as the "New Labour Codes"). These New Labour Codes became effective from November 21, 2025.The Company assessed the implications of the New Labour Codes and made an additional provision of? 243.46 million for gratuity and leave liability towards employee benefits during the quarter ended December 31, 2025, and year ended March 31, 2026. Considering the regulatory driven and non - recurring nature of the impact, the Company presented the incremental impact as an "Exceptional item".4. The figures of the quarter ended March 31, 2026 are the balancing figures between audited figures in respect of the full previous financial year and the published unaudited year-to-date figures up to the end of the third quarter of the previous financial year, which were subjected to a limited review.5. The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108- 'Operating Segments'.6. The previous periods/year numbers have been regrouped/rearranged wherever necessary to conform with the current period presentation.7. The above Unaudited Standalone Financial Results of the Company are available on the Company’s website www.glandpharma.comand also on the website of BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com),where the equity shares of the Company are listed. mu.★/ GLAND]\<? For and on behalf of the BoardGland Pharma Limited Srinivas SaduExecutive ChairmanDIN No. 06900659 HyderabadAugust 10, 2026
Page 9
Press Release Gland Pharma Reports Yet Another Quarter with Record Revenues Revenue Growth @ 20% Y-o-Y | PAT Growth @ 47% Y-o-Y Hyderabad, August 10th, 202 6: Gland Pharma Limited (BSE: 543245 | NSE: GLAND), a n injectable-focused pharmaceutical company, announced its financial results for the first quarter and year ended June 30th, 2026. Commenting on the results, Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Our strong start to FY27 reflects the successful execution of our CDMO strategy and the resilience of our B2B business model. Growth was driven by recent product launches from CDMO portfolio and strong customer demand for our diversified product mix . We continue to strengthen our growth platform through a robust CDMO pipeline including investments in differentiated technologies and capacity expansions, which position us well for sustainable long-term growth.” Consolidated Financial Performance Particulars Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ Revenue from operations 18,003 15,056 20% 17,428 3% Gross Profit(1) 11,759 9,845 19% 11,515 2% Gross Profit margin (%) 65% 65% 66% EBITDA(2) 4,930 3,678 34% 5,130 -4% EBITDA margin (%)(3) 27% 24% 29% Adj. EBITDA(4) 5,102 3,737 37% 5,244 -3% Adj. EBITDA margin (%) 28% 25% 30% PBT 4,350 3,127 39% 5,058 -14% PBT margin (%) 24% 21% 29% PAT 3,170 2,155 47% 3,667 -14% PAT margin (%) 18% 14% 21% 1. Gross Profit = Revenue from Operations – Materials consumed; 2. EBITDA = Profit before tax plus finance expense plus depreciation and amortization expense excluding o ther income and forex losses. 3. EBITDA margin = EBITDA / Revenue from operations; 4.Adj. EBITDA = EBITDA plus Employee stock option compensation expenses. Financial Highlights: • Quarterly revenue increased by 20% year-on-year. • Quarterly R&D investments stood at ₹ 772 million. • Quarterly adj. EBITDA increased by 37% year-on-year. • Quarterly adj. EBITDA margin stood at 28%. • Quarterly PAT increased by 47% year-on-year. • Quarterly PAT margin increased by ~330 bps year-on-year. • CDMO business contributed 50% of revenues and grew by 20% year-on-year in Q1FY27. • B2B* business contributed 50% of revenues and grew by 19% year-on-year in Q1FY27. * Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26. ₹ Mn Press Release GLANDGland Pharma Reports Yet Another Quarter with Record RevenuesRevenue Growth @ 20% Y-o-Y | PAT Growth @ 47% Y-o-YHyderabad, August 10th, 2026: Gland Pharma Limited (BSE: 543245 | NSE: GLAND), an injectable-focusedpharmaceutical company, announced its financial results for the first quarter and year ended June 30th, 2026.Commenting on the results, Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, stated, “Our strong startto FY27 reflects the successful execution of our CDMO strategy and the resilience of our B2B businessmodel. Growth was driven by recent product launches from CDMO portfolio and strong customer demandfor our diversified product mix. l/l/e continue to strengthen our growth platform through a robust CDMOpipeline including investments in differentiated technologies and capacity expansions, which position uswell for sustainable long-term growth.”Consolidated Financial PerformancetMnI ParticularsQ1 FY27Q1 FY26YoYQ4 FY26QoQ 1Revenue from operations18,00315,05620%17,4283%Gross Profit(1) 11,7599,84519%11,5152%Gross Profit margin (%) 65%65% 66%EBITDA(2) 4,9303,67834%5,130-4%EBITDA margin (%)<3> 27%24% 29%Adj. EBITDA(4) 5,1023,73737%5,244-3%Adj. EBITDA margin (%) 28%25% 30%PBT 4,3503,12739%5,058-14%PBT margin (%) 24%21% 29%PAT 3,1702,15547%3,667-14%PAT margin (%) 18%14% 21%1. Gross Profit = Revenue from Operations - Materials consumed; 2. EBITDA = Profit before tax plus finance expense plus depreciation and amortization expense excluding other income andforex losses. 3. EBITDA margin = EBITDA / Revenue from operations; 4.Adj. EBITDA = EBITDA plus Employee stock option compensation expenses. Financial Highlights: Quarterly revenue increased by 20% year-on-year. Quarterly R&D investments stood at ? 772 million. Quarterly adj. EBITDA increased by 37% year-on-year. Quarterly adj. EBITDA margin stood at 28%. Quarterly PAT increased by 47% year-on-year. Quarterly PAT margin increased by -330 bps year-on-year. CDMO business contributed 50% of revenues and grew by 20% year-on-year in Q1FY27. B2B* business contributed 50% of revenues and grew by 19% year-on-year in Q1FY27. Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.
Page 10
Press Release Business-wise Performance Business Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ CDMO 8,915 7,411 20% 8,059 11% B2B* 9,088 7,645 19% 9,369 -3% Total 18,003 15,056 20% 17,428 3% * Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26. Market-wise Performance Markets Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ USA 9,810 7,443 32% 9,807 0% Europe 3,954 3,302 20% 3,814 4% Canada, Australia and New Zealand (Other Core Markets) 534 739 -28% 588 -9% India 666 594 12% 670 -1% Rest of the world 3,039 2,978 2% 2,549 19% TOTAL 18,003 15,056 20% 17,428 3% Business Highlights: • R&D Expenses: Total R&D expenses were ₹772 million in Q1 FY27, representing 4% of consolidated revenue. The R&D expenditure was mainly focused on complex product development and the number of filings. • New Launches: The company launched 4 molecules in the USA this quarter, including Multi -Vitamin and Leucovorin calcium. • Filings and Approvals: Three ANDAs were filed, and seven were approved in Q1 FY27, contributing to a cumulative total of 389 ANDA filings in the U.S. (342 approved, 47 pending). • In-house Complex Pipeline: Six products have already been launched, and three more are in line for approval. Complex injectables are expected to remain a central pillar of long -term growth, with more products being added to the pipeline. • Co-development Partnerships: Fifteen products are in co -development (seven 505(b)(2) and eight ANDAs), with commercialization anticipated to begin in FY28. • Ready-to-Use (RTU) Bags: Filed 21 Ready-to-Use infusion bag products and received approval for 18 so far. An additional 11 are currently under development. The total RTU bag portfolio addresses a market opportunity of approximately $644 million in the US. • CDMO partnership with A Global Pharmaceutical Company: Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90 –100 million. Technology transfer activities are planned for completion within two years, with revenues expected to commence from calendar year 2029. • Strategic collaboration with Neuland Laboratories: Long-term strategic collaboration for the manufacturing of sterile APIs for microparticle depot products. • In-licensing agreement with a China-based development company for the development, manufacturing and commercialization of a niche liposomal product for the U.S. and European markets. ₹ Mn ₹ Mn Press Release GLAND Business-wise PerformancefMnBusinessQ1 FY27Q1 FY26YoYQ4 FY26QoQCDMO8,9157,41120%8,05911%B2B* 9,0887,64519%9,369-3%Total 18,00315,05620%17,4283%* Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26. Market-wise PerformanceZMnMarketsQ1 FY27Q1 FY26YoYQ4 FY26QoQUSA 9,8107,44332%9,8070%Europe3,9543,30220%3,8144%Canada, Australia and NewZealand (Other Core Markets)534739-28%588-9%India 66659412%670-1%Rest of the world3,0392,9782%2,54919%TOTAL18,00315,05620%17,4283%Business Highlights: R&D Expenses: Total R&D expenses were ?772 million in Q1 FY27, representing 4% of consolidatedrevenue. The R&D expenditure was mainly focused on complex product development and the number offilings. New Launches: The company launched 4 molecules in the USA this quarter, including Multi-Vitamin andLeucovorin calcium. Filings and Approvals: Three ANDAs were filed, and seven were approved in Q1 FY27, contributing to acumulative total of 389 ANDA filings in the U.S. (342 approved, 47 pending). In-house Complex Pipeline: Six products have already been launched, and three more are in line forapproval. Complex injectables are expected to remain a central pillar of long-term growth, with moreproducts being added to the pipeline. Co-development Partnerships: Fifteen products are in co-development (seven 505(b)(2) and eightANDAs), with commercialization anticipated to begin in FY28. Ready-to-Use (RTU) Bags: Filed 21 Ready-to-Use infusion bag products and received approval for 18 sofar. An additional 11 are currently under development. The total RTU bag portfolio addresses a marketopportunity of approximately $644 million in the US. CDMO partnership with A Global Pharmaceutical Company: Once all products are commercialized, theannualized revenue potential is expected to be approximately USD 90-100 million. Technology transferactivities are planned for completion within two years, with revenues expected to commence from calendaryear 2029. Strategic collaboration with Neuland Laboratories: Long-term strategic collaboration for themanufacturing of sterile APIs for microparticle depot products. In-licensing agreement with a China-based development company for the development, manufacturingand commercialization of a niche liposomal product for the U.S. and European markets.
Page 11
Press Release Earnings Call Details The Company will conduct an Earnings call at 6.30 PM (IST) on August 10th, 202 6, to discuss the business performance and answer participants' questions. To participate in this conference call, please dial the numbers provided below ten minutes before the scheduled start time. Universal Access +91 22 6280 1516 / +91 22 7115 8875 Diamond pass link Click here to register National Toll-Free 1 800 120 1221 International Toll-Free Number USA – 18667462133 UK – 08081011573 Singapore – 8001012045 Hong Kong – 800964448 About Gland Pharma Limited (BSE: 543245, NSE: GLAND) Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small -volume liquid parenteral products to become one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It operates primarily under a Contract Development & Manufacturing Operations (CDMO), Business-to-Business (B2B) model and has an excellent track record in the development, manufacturing, and marketing of sterile injectables. It has a wide range of injectables, including vials, ampoules, pre -filled syringes, lyophilized vials, dry powders, infusions, on cology, and ophthalmic solutions, and also enjoys the distinction of having pioneered Heparin technology in India. For more information, log on to: www.glandpharma.com Investor Contacts Sampath Kumar Pallerlamudi Company Secretary and Compliance Officer Shriniwas P. Dange Investor Relations investors@glandpharma.com This press release may include statements of future expectations and other forward -looking statements based on management's current expectations and beliefs. Actual results may vary materially from those expressed or implied by the statements herein due to changes in economic, business, competitive, technological, and/or regulatory factors. Gland Pharma Limited, its directors and any of the affiliates or employee is under no obligation to, and expressly assume any obligation to update any particular forward-looking statement contained in this release. Press Release GLAND Earnings Call DetailsThe Company will conduct an Earnings call at 6.30 PM (1ST) on August 10th, 2026, to discuss the businessperformance and answer participants' questions. To participate in this conference call, please dial the numbersprovided below ten minutes before the scheduled start time.Universal Access+91 22 6280 1516 / +91 22 7115 8875Diamond pass link Click here to registerNational Toll-Free1 800 120 1221International Toll-Free NumberUSA - 18667462133UK -08081011573Singapore -8001012045Hong Kong - 800964448About Gland Pharma Limited (BSE: 543245, NSE: GLAND)Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturerof small-volume liquid parenteral products to become one of the largest and fastest-growing injectable-focusedcompanies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India,and other markets. It operates primarily under a Contract Development & Manufacturing Operations (CDMO),Business-to-Business (B2B) model and has an excellent track record in the development, manufacturing, andmarketing of sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes,lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions, and also enjoys the distinction ofhaving pioneered Heparin technology in India. For more information, log on to: www.glandpharma.comInvestor Contacts Sampath Kumar PallerlamudiCompany Secretary and Compliance OfficerShriniwas P. DangeInvestor Relationsinvestors@qlandpharma.com This press release may include statements of future expectations and other forward-looking statements based on management's currentexpectations and beliefs. Actual results may vary materially from those expressed or implied by the statements herein due to changes ineconomic, business, competitive, technological, and/or regulatory factors. Gland Pharma Limited, its directors and any of the affiliates oremployee is under no obligation to, and expressly assume any obligation to update any particular forward-looking statement contained in thisrelease.
Page 12
Investor Presentation Q1 FY27 10th August 2026 GLAND PHARMA |GLAND| GLAND PHARMA InvestorPresentationQ1 FY2710thAugust 2026
Page 13
2 Safe Harbour Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. This presentation may include certain “forward looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India and any other country, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein. No part of this presentation may be reproduced, quoted or circulated without prior written approval from Gland Pharma Limited. 2 Safe Harbour Statement The Presentation is to provide the general background information about theCompany’s activities as at the date of the Presentation. The informationcontained herein is for general information purposes only and based onestimates and should not be considered as a recommendation that any investorshould subscribe / purchase the company shares.This presentation may include certain “forward looking statements’’. Thesestatements are based on current expectations, forecasts and assumptions thatare subject to risks and uncertainties which could cause actual outcomes andresults to differ materially from these statements. Important factors that couldcause actual results to differ materially from our expectations include, amongstothers general economic and business conditions in India and any othercountry, ability to successfully implement our strategy, our research anddevelopment efforts, our growth and expansion plans and technologicalchanges, changes in the value of the Rupee and other currencies, changes inthe Indian and international interest rates, change in laws and regulations thatapply to the Indian and global pharmaceuticals industries, increasingcompetition, changes in political conditions in India or any other country andchanges in the foreign exchange control regulations in India. Neither thecompany, nor its directors and any of the affiliates or employee have anyobligation to update or otherwise revise any forward-looking statements. Thereaders may use their own judgment and are advised to make their owncalculations before deciding on any matter based on the information givenherein.No part of this presentation may be reproduced, quoted or circulated withoutprior written approval from Gland Pharma Limited. 2
Page 14
Financial Highlights GLAND Financial Highlights
Page 15
4 1.Gross Profit = Revenue from Operations – Materials consumed; 2. EBITDA = Profit before tax plus finance expense plus depreciation and amortization expense, excluding other income and forex losses. 3. EBITDA margin = EBITDA / Revenue from operations;4. Adj. EBITDA = EBITDA plus Employee stock option compensation expenses. Consolidated P&L ₹ Mn Particulars Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ Revenue from operations 18,003 15,056 20% 17,428 3% Other Income 612 575 6% 1,115 -45% Total Income 18,615 15,631 19% 18,543 0% Gross Profit(1) 11,759 9,845 19% 11,515 2% Gross Profit margin (%) 65% 65% 66% EBITDA(2) 4,930 3,678 34% 5,130 -4% EBITDA margin(%)(3) 27% 24% 29% Adj.EBITDA(4) 5,102 3,737 37% 5,244 -3% Adj. EBITDA margin(%) 28% 25% 30% PBT 4,350 3,127 39% 5,058 -14% PBT margin(%) 24% 21% 29% PAT 3,170 2,155 47% 3,667 -14% PAT margin(%) 18% 14% 21% Consolidated P&L ?MnParticularsQ1 FY27Q1 FY26YoYQ4 FY26QoQRevenue from operations18,00315,05620%17,4283%Other Income6125756%1,115-45%Total Income18,61515,63119%18,5430%Gross Profit(1) 11,7599,84519%11,5152%Gross Profit margin (%)65% 65%66%EBITDA*2’ 4,9303,67834%5,130-4%EBITDA margin(%)(3) 27%24%, 29%Adj.EBITDA*4’ 5,1023,73737%5,244-3%Adj. EBITDA margin(%)28% 25%30%PBT 4,3503,12739%5,058-14%PBT margin(%)24%21%, 29%PAT 3,1702,15547%3,667-14%PAT margin(%)18%,14%, 21% -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 41. Gross Profit = Revenue from Operations - Materials consumed; 2. EBITDA = Profit before tax plus finance expense plus depreciation and amortization expense, excluding other income and forex losses. 3. EBITDA margin = EBITDA / Revenuefrom operations;4. Adj. EBITDA = EBITDA plus Employee stock option compensation expenses.
Page 16
5 Consolidated Financial Highlights (1/3) 1.Gross Profit = Revenue from Operations – Materials consumed 2. Gross Profit Margin = Gross profit /Revenue from operations 3. Adj. EBITDA = EBITDA plus Employee stock option compensation expenses.. 4. Adj. EBITDA margin = Adj. EBITDA / Revenue from operations. Revenue from Operations (₹ Mn) Gross Profit(1) / Gross Profit Margin(2) (₹ Mn / %) 15,056 17,428 18,003 Q1 FY26 Q4 FY26 Q1 FY27 9,845 11,515 11,759 Q1 FY26 Q4 FY26 Q1 FY27 65% 65% 66% Adj. EBITDA(3) / Adj. EBITDA Margin(4) / PAT / PAT Margin (₹ Mn / %) R&D Expenditure (₹ Mn / % of Consolidated revenue) 3,737 5,244 5,102 2,155 3,667 3,170 Q1 FY26 Q4 FY26 Q1 FY27 14% 28% 25% Adj. EBITDA PAT 30% 21% 18% 664 723 772 Q1 FY26 Q4 FY26 Q1 FY27 4% 4% 4% Consolidated Financial Highlights (1/3) Revenue from Operations(< Mn) Gross Profit*1) / Gross Profit Margin*2)(< Mn / %)18,00317,42815,056 Q1 FY26Q4 FY26Q1 FY27 11,75911,5159,845 65%66%65% Q1 FY26Q4 FY26Q1 FY27R&D Expenditure(? Mn / % of Consolidated revenue)Adj. EBITDA*3) / Adj. EBITDA Margin*4) / PAT / PAT Margin(? Mn / %) 5,244 5,102 772723664 4%4%4%3,73730%3,66728%3,17018% I--------- 25%2,15514% 21% Q1 FY26 Q4 FY26 Q1 FY27Q1 FY26 Q4 FY26 Q1 FY27■ ■ Adj. EBITDA ■ PAT 1. Gross Profit = Revenue from Operations - Materials consumed 2. Gross Profit Margin = Gross profit /Revenue from operations 3. Adj. EBITDA = EBITDA plus Employee stock option compensation expenses.. 4. Adj. EBITDA margin = Adj.EBITDA / Revenue from operations.
Page 17
6 Consolidated Financial Highlights (2/3) Net Worth(1) (₹ Mn) 1.Net Worth refers to sum of equity share capital and other equity. 2. Return on Capital Employed (ROCE) = EBIT/ Average Capital Employed for the period. Capital Employed represents Total Assets – Current Liabilities; 3. Return on Net Worth (RONW) = Profit for the period / Average Net Worth for the period. Net Worth represents sum of equity share capital and other equity. 4. Asset Turnover is calculated as Revenue from operations for the period divided by average total assets for the period; 5. Fixed Asset Turnover is calculated as Revenue from operations for the period divided by average total fixed assets for the period (Property, plant and equipment + Right-of-use assets + Capital work in progress) 91,507 103,580 106,762 FY25 FY26 Jun'26 ROCE(2) / RONW(3) (%) 9% 11% 14% 8% 11% 12% 0.0% 5.0% 10.0% 15.0% FY25 FY26 Jun'26 RoCE RoNW Asset Turnover Ratio(4)(5) (x) 0.5 1.4 0.5 1.5 0.6 1.6 Total asset turnover Fixed asset turnover FY25 FY26 Jun'26 Capital Expenditure (₹ Mn) 786 1,373 1,132 Q1 FY26 Q4 FY26 Q1 FY27 Consolidated Financial Highlights (2/3) Net Worth(1)(? Mn) ROCE(2)/RONW(3)(%) RoCERoNW14%11%9% 12%11%8% 103,580106,76291,507 FY25FY26Jun'26 FY25FY26Jun’26Asset Turnover Ratio(4)(5)(X)Capital Expenditure(? Mn) 1,373786 0.60.50.5Total asset turnover Fixed asset turnoverFY25 «FY26 ■ Jun'26Q1 FY26Q4 FY26Q1 FY27-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 6I.Net Worth refers to sum of equity share capital and other equity. 2. Return on Capital Employed (ROCE) = EBIT/ Average Capital Employed for the period. Capital Employed represents Total Assets - Current Liabilities; 3. Return on Net Worth(RONW) = Profit for the period I Average Net Worth for the period. Net Worth represents sum of equity share capital and other equity. 4. Asset Turnover is calculated as Revenue from operations for the period divided by average total assets forthe period; 5. Fixed Asset Turnover is calculated as Revenue from operations for the period divided by average total fixed assets for the period (Property, plant and equipment + Right-of-use assets + Capital work in progress)
Page 18
7 Consolidated Financial Highlights (3/3) Cash Conversion Cycle (CCC)(3)(4) (# of Days) Cash Flow from Operations (₹ Mn) 100 97 94 138 130 122 -66 -63 -61 172 164 155 FY25 FY26 Jun'26 Receivable days Inventory days Payable days Cash conversion cycle 2,620 4,045 3,183 Q1 FY26 Q4 FY26 Q1 FY27 1. Net Cash refers to Cash and Cash equivalents less total borrowings(including current maturities). 2. Net Working Capital refers to Current assets (excluding cash and bank balances) less Current liabilities. 3. COGS mean cost of goods sold includes cost of materials consumed, purchases of traded goods, change in inventories of finished goods, traded goods and work-in-progress and manufacturing overheads; 4. Receivable days calculated as average trade receivables for the period divided by revenue from operations * over 90/365 days (as applicable), Inventory days calculated as average inventory for the period divided by COGS* over 90/365 days (as applicable), & Payable days calculated as average trade payable for the period divided by COGS* over 90/365 days (as applicable). CCC is calculated as Receivable days + Inventory days - Payable days. Cash and Bank Balances / Net Cash(1) (₹ Mn) 25,562 33,591 35,466 22,870 31,157 32,939 FY25* FY26 Jun'26 Total Cash Net Cash Net Working Capital(2) (₹ Mn) 21,683 24,855 25,932 FY25 FY26 Jun'26 . * Excluding non-callable deposits of INR 3,960 million. Consolidated Financial Highlights (3/3)Cash Flow from Operations(? Mn)Cash and Bank Balances / Net Cash(1)■■Total Cash(? Mn) Net Cash 4,04535,466 32,93933,59131 15725,562 22,870 Q1 FY26 Q4 FY26 Q1 FY27FY25* FY26. * Excluding non-callable deposits of INR 3,960 million.Jun'26 Net Working Capital(2)(? Mn) Cash Conversion Cycle (CCC)(3)(4)(# of Days)24,855 25,93221,683 172 16413097-63FY26 155138 122100 94-61-66FY25 Jun'26FY25 FY26 Jun'26 Cash conversion cycleReceivable days Inventory days Payable days 1. Net Cash refers to Cash and Cash equivalents less total borrowings(including current maturities). 2. Net Working Capital refers to Current assets (excluding cash and bank balances) less Current liabilities. 3. COGS mean cost of goods soldincludes cost of materials consumed, purchases of traded goods, change in inventories of finished goods, traded goods and work-in-progress and manufacturing overheads; 4. Receivable days calculated as average trade receivables for theperiod divided by revenue from operations * over 90/365 days (as applicable), Inventory days calculated as average inventory for the period divided by COGS* over 90/365 days (as applicable), & Payable days calculated as average trade payablefor the period divided by COGS* over 90/365 days (as applicable). CCC is calculated as Receivable days + Inventory days - Payable days.
Page 19
Business Update GLAND Business Update
Page 20
9 Business-wise Revenue Break-up ₹ Mn Business Q1 FY27 Q1 FY26 YoY Q4 FY26 QoQ CDMO 8,915 7,411 20% 8,059 11% B2B* 9,088 7,645 19% 9,369 -3% Total 18,003 15,056 20% 17,428 3% Business Update • CDMO growth supported by recent product launches. • B2B growth supported by increased demand from existing customers and higher volume. Revenue Distribution 50%50% Q1 FY27 49%51% Q1 FY26 46% 54% Q4 FY26 CDMOB2B * Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26. Business-wise Revenue Break-up?MnBusinessQ1 FY27Q1 FY26YoYQ4 FY26QoQCDMO8,9157,41120%8,05911%B2B* 9,0887,64519%9,369-3%Total 18,00315,05620%17,4283% Revenue DistributionBusiness Update CDMO growth supported by recent productlaunches. B2B growth supported by increaseddemand from existing customers andhigher volume. Q4FY2646%54%Q1FY2750%50% Q1FY2649%51% B2B 1CDMO 9Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.
Page 21
10 Business Updates • R&D Expenses: Total R&D expenses were ₹772 million in Q1 FY27, representing 4% of consolidated revenue. The R&D expenditure was mainly focused on complex product development and the number of filings. • New Launches: The company launched 4 molecules in the USA this quarter, including Multi-Vitamin and Leucovorin calcium. • Filings and Approvals: Three ANDAs were filed, and seven were approved in Q1 FY27, contributing to a cumulative total of 389 ANDA filings in the U.S. (342 approved, 47 pending). • In-house Complex Pipeline: Six products have already been launched, and three more are in line for approval. Complex injectables are expected to remain a central pillar of long-term growth, with more products being added to the pipeline. • Co-development Partnerships: Fifteen products are in co-development (seven 505(b)(2) and eight ANDAs), with commercialization anticipated to begin in FY28. • Ready-to-Use (RTU) Bags: Filed 21 Ready-to-Use infusion bag products and received approval for 18 so far. An additional 11 are currently under development. The total RTU bag portfolio addresses a market opportunity of approximately $644 million in the US. • CDMO partnership with A Global Pharmaceutical Company: Once all products are commercialized, the annualized revenue potential is expected to be approximately USD 90–100 million. Technology transfer activities are planned for completion within two years, with revenues expected to commence from calendar year 2029. • Strategic collaboration with Neuland Laboratories: Long-term strategic collaboration for the manufacturing of sterile APIs for microparticle depot products. • In-licensing agreement with a China-based development company for the development, manufacturing and commercialization of a niche liposomal product for the U.S. and European markets. Business Updates * ; R&D Expenses: Total R&D expenses were 772 million in Q1 FY27, representing 4% of consolidated revenue. The R&D expenditure wasmainly focused on complex product development and the number of filings. New Launches: The company launched 4 molecules in the USA this quarter, including Multi-Vitamin and Leucovorin calcium. Filings and Approvals: Three ANDAs were filed, and seven were approved in Q1 FY27, contributing to a cumulative total of 389 ANDAfilings in the U.S. (342 approved, 47 pending). In-house Complex Pipeline: Six products have already been launched, and three more are in line for approval. Complex injectables areexpected to remain a central pillar of long-term growth, with more products being added to the pipeline. Co-development Partnerships: Fifteen products are in co-development (seven 505(b)(2) and eight ANDAs), with commercializationanticipated to begin in FY28. Ready-to-Use (RTU) Bags: Filed 21 Ready-to-Use infusion bag products and received approval for 18 so far. An additional 11 arecurrently under development. The total RTU bag portfolio addresses a market opportunity of approximately $644 million in the US. CDMO partnership with A Global Pharmaceutical Company: Once all products are commercialized, the annualized revenue potentialis expected to be approximately USD 90-100 million. Technology transfer activities are planned for completion within two years, withrevenues expected to commence from calendar year 2029. Strategic collaboration with Neuland Laboratories: Long-term strategic collaboration for the manufacturing of sterile APIs formicroparticle depot products.In-licensing agreement with a China-based development company for the development, manufacturing and commercialization of aniche liposomal product for the U.S. and European markets. 10|CLAND|
Page 22
Geographical Revenue GLAND GeographicalRevenue
Page 23
12 US Filings Update US Contribution Business Update B2B US Market Q1FY27 Cumulative ANDAs(1) - Filed 3 389 - Approved 7 342 54% Q1 FY27 Revenue Contribution CDMO 7,443 9,807 9,810 Q1 FY26 Q4 FY26 Q1 FY27 Note: 1. ANDA count includes technology transfer ANDAs. ₹ Mn 32% YoY 1,794 2,236 2,653 Q1 FY26 Q4 FY26 Q1 FY27 48% YoY 5,649 7,571 7,157 Q1 FY26 Q4 FY26 Q1 FY27 27% YoY • CDMO: Growth driven by recent product launches – Dalbavancin and Multi-Vitamin; • B2B: Volume expansion in existing products, including Enoxaparin, Vancomycin, Chlorothiazide and Heparin. • New Product Launches: Launched 4 molecules. US Market ? MnRevenue Contribution CDMO B2B48% YoY 27% YoY32% YoY 7,5717,1572,6532,236 5,6499,8079,810 1,7947,443 Q1 FY26Q4 FY26Q1 FY27 Q1 FY26Q4 FY26Q1 FY27Q1 FY26Q4 FY26Q1 FY27 US Filings UpdateUS ContributionBusiness UpdateQ1FY27 Cumulative CDMO: Growth driven by recent productlaunches - Dalbavancin and Multi-Vitamin; B2B: Volume expansion in existing products,including Enoxaparin, Vancomycin,Chlorothiazide and Heparin. New Product Launches: Launched 4 molecules.54%ANDAs(1) - Filed 3 389- Approved 7 342 ND|Note: 1. ANDA count includes technology transfer ANDAs. 12
Page 24
13 Europe Contribution Europe Market 22% Q1 FY27 ₹ Mn Business Update • Volume expansion in existing products, including Daptomycin and Cenexi CDMO products. • Recent product launch – Dalbavancin. B2BRevenue Contribution CDMO 3,302 3,814 3,954 Q1 FY26 Q4 FY26 Q1 FY27 20% YoY 3,267 3,791 3,916 Q1 FY26 Q4 FY26 Q1 FY27 20% YoY 36 23 38 Q1 FY26 Q4 FY26 Q1 FY27 6% YoY Europe Market tMnB2BRevenue ContributionCDMO 6% YoY20% YoY20% YoY 363,9163,791 23 Q4 FY26 Q4 FY26Q1 FY27Q1 FY26 3,9543,8143,302 3,267 Q4 FY26Q1 FY27Q1 FY26 Q1 FY26 Q1 FY27 Europe ContributionBusiness Update Volume expansion in existing products, includingDaptomycin and Cenexi CDMO products. Recent product launch - Dalbavancin. 22% 13
Page 25
14 Other Core Markets Contribution Business Update Other Core Markets (Canada, Australia and New Zealand) 3% Q1 FY27 ₹ Mn • Volume decline in the existing products led to revenue degrowth. B2BRevenue Contribution CDMO 739 588 534 Q1 FY26 Q4 FY26 Q1 FY27 -28% YoY 363 274 199 Q1 FY26 Q4 FY26 Q1 FY27 -45% YoY 376 314 335 Q1 FY26 Q4 FY26 Q1 FY27 -11% YoY Other COPG Markets (Canada, Australia and New Zealand)? MnRevenue Contribution CDMO B2B-28% YoY -45% YoY -11% YoY739 376363 335314588 274534 199 Q1 FY26Q4 FY26Q1 FY27 Q1 FY26Q4 FY26Q1 FY27Q1 FY26Q4 FY26Q1 FY27 Business UpdateVolume decline in the existing products led to revenuedegrowth. Other Core Markets Contribution3%Q1FY27 14|CLAND|
Page 26
15 RoW Contribution Business Update Rest of the World 17% Q1 FY27 ₹ Mn • Growth seen across some of the key products, including Heparin, Huminsulin and Rocuronium Bromide. B2BRevenue Contribution CDMO 2,978 2,549 3,039 Q1 FY26 Q4 FY26 Q1 FY27 2% YoY 1,677 1,340 1,664 Q1 FY26 Q4 FY26 Q1 FY27 -1% YoY 1,301 1,209 1,375 Q1 FY26 Q4 FY26 Q1 FY27 6% YoY Rest of the World tMnB2BRevenue ContributionCDMO-1% YoY 6% YoY2% YoY 1,3751,3011,664 1,209 Q1 FY27Q1 FY26Q4 FY26Q1 FY27 1,6773,0392,978 1,3402,549 Q4 FY26Q1 FY27Q1 FY26 Q1 FY26Q4 FY26 RoW ContributionBusiness Update 17%Q1FY27 Growth seen across some of the keyproducts, including Heparin, Huminsulinand Rocuronium Bromide. 15ICLANDj
Page 27
16 India Contribution Business Update India 4% Q1 FY27 ₹ Mn • Growth seen in CDMO for certain products, including Huminsulin. • Decline in B2B due to lower sales of Enoxaparin. B2B*Revenue Contribution CDMO 594 670 666 Q1 FY26 Q4 FY26 Q1 FY27 12% YoY 310 419 483 Q1 FY26 Q4 FY26 Q1 FY27 56% YoY 284 251 183 Q1 FY26 Q4 FY26 Q1 FY27 -36% YoY * Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26. India tMnB2B*Revenue ContributionCDMO12% YoY 56% YoY -36% YoY284251483 183 Q1 FY27Q1 FY26Q4 FY26Q1 FY27 666 419310 Q1 FY26 Q4 FY26Q1 FY27 Q1 FY26Q4 FY26 India ContributionBusiness UpdateGrowth seen in CDMO for certain products,including Huminsulin.Decline in B2B due to lower sales ofEnoxaparin. 4%Q1FY27 16Including B2C Revenue INR 152 Mn in Q1FY27, INR 147 Mn in Q1FY26, INR 147 Mn in Q4FY26.
Page 28
Thank You Gland Pharma Limited Plot No. 11 & 84, TSIIC Phase: IV Pashamylaram (V), Patancheru (M), Sangareddy District Hyderabad 502307, Telangana, India Corporate Office 543245 GLAND GLAND:IN Shriniwas P. Dange Investor Relations investors@glandpharma.com Investor Relations 17 GLAND PHARMA Sampath Kumar Pallerlamudi Company Secretary & Compliance Officer 17 iGiANPl GLAND PHARMA Thank You Investor RelationsSampath Kumar PallerlamudiCompany Secretary & Compliance OfficerShriniwas P. DangeInvestor Relationsinvestors@glandpharma.com Corporate OfficeGland Pharma LimitedPlot No. 11 & 84, TSIIC Phase: IVPashamylaram (V), Patancheru (M),Sangareddy DistrictHyderabad 502307, Telangana, India 3SE 5432450 NSE GLANDBloomberg 3LANDJN